Roivant's Dermavant to be acquired by Organon for $1.2B

Roivant Sciences Ltd.

Organon (OGN) will acquire Dermavant, a Roivant (ROIV) subsidiary, for $1.2B in cash and milestone payments.
Deal includes VTAMA cream (tapinarof) 1%, approved for plaque psoriasis in adults (May 2022).
sNDA for atopic dermatitis under FDA review; PDUFA decision expected Q4 2024.
VTAMA is a once-daily steroid-free topical with no safety label warnings or duration/BSA restrictions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.